GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 1,330,000 shares, a growth of 341.9% from the October 31st total of 301,000 shares. Based on an average daily volume of 1,900,000 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GOVX shares. Noble Financial upped their price objective on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. Alliance Global Partners initiated coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective for the company. D. Boral Capital reissued a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research note on Friday, November 15th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and an average target price of $14.20.

GeoVax Labs Price Performance

NASDAQ GOVX traded down $0.07 during midday trading on Friday, hitting $2.64. The company had a trading volume of 487,867 shares, compared to its average volume of 2,460,829. The firm has a 50-day moving average price of $2.34 and a 200-day moving average price of $2.68. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period in the prior year, the firm earned ($4.80) earnings per share. As a group, equities analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.